drugset
drugset / Trial / NCT01545050

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

NCT01545050 ↗

Phase 2 Terminated 72 enrolled CSL Behring
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.

Timeline

Start
2012-06
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clazakizumab Monoclonal antibody 100 mg Intravenous
Subject Clazakizumab Monoclonal antibody 150 mg Intravenous
Subject Clazakizumab Monoclonal antibody 200 mg Intravenous
Subject Clazakizumab Monoclonal antibody 300 mg Intravenous
Subject Clazakizumab Monoclonal antibody 400 mg Intravenous
Subject Clazakizumab Monoclonal antibody 600 mg Intravenous

Indications

Crohn disease